Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Pharmacodynamics of SHR-3167 in Type 2 Diabetes
NCT07032688Phase 1Recruiting
- Sponsor
- Hengrui
- Start
- Aug 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of SHR-3167 in type 2 diabetes mellitus (T2DM), sponsored by Hengrui. Primary endpoint: Area under the concentration-time curve at steady state at 168 hours. Started Aug 2025; status: recruiting.
02
Drugs
SHR-3167
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07032688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07032688.